CEO sales are mechanically tied to option exercises (cashless exercise-and-sell pattern) and are immaterial relative to market cap. The Q2 revenue miss and Tyvaso competitive headwinds are the more relevant near-term catalysts. Monitor upcoming ralinepag and Nebulized Tyvaso NDA decisions for pipeline-driven upside.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 12 $511.72entry
- T+1 · 3mo ago −2.04%α −2.74% · $501.27
- T+5 · 3mo ago +3.40%α +3.85% · $529.14
- T+20 · 2mo ago −1.54%α +0.36% · $503.86
- T+60 · 12d ago +10.55%α +15.66% · $565.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Martine Rothblatt sold ~$5.5M in open-market shares on August 10, 2026, following option exercises, while EVP Paul Mahon sold $682K on August 6. The cluster follows a mixed Q2 earnings report (revenue miss, EPS beat) and represents 0.025% of market cap, trivial in proportion. The CEO's sales are likely liquidity-driven after derivative exercises, not a bearish signal.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold 7,500 open-market shares for ~$5.5M on Aug 10, 2026, alongside exercising 19,000 options (9,500 at $0, 9,500 at $135.42)
- EVP Paul Mahon sold 1,300 shares for $682K on Aug 6, 2026
- Total cluster open-market sales: ~$6.2M, representing 0.028% of $22.1B market cap
- Q2 2026 revenue of $783.3M missed $804.6M consensus by 2.7%; EPS of $7.27 beat $6.86 estimate by 5.9%
- Tyvaso sales declined 4% YoY, with Nebulized Tyvaso down 18% YoY
Financial Impact
Open-market sales of ~$6.2M represent 0.028% of $22.1B market cap, trivial and routine
Risk Factors
- Tyvaso franchise facing competitive pressure in inhaled prostacyclin class
- Revenue decline of 2% YoY may signal market share loss
- CEO's consistent option-exercise-and-sell pattern could continue, creating modest overhang
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1786525314104 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers